Clinical trials: HIV/AIDS Prevention
HIV Prevention, HIV Infections
Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
The purpose of this program is to evaluate an effort to provide a comprehensive package of HIV prevention services of which post-exposure prophylaxis (medicines that may help prevent HIV infection after an exposure) can be a…
- Trial name
- NCT00949234
- Testing
- tenofovir + emtricitabine, lopinavir/ritonavir
- Where
- 2 sites in United States
- Volunteers
- 267 people
- Sponsor
- University of California, Los Angeles
HIV
Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda
This randomized controlled pilot study of the "Game Changers" program will: 1. Assess the feasibility and acceptability of implementing an HIV prevention advocacy intervention with people living with HIV who are in HIV care, and…
- Trial name
- NCT03435497
- Testing
- Game Changers
- Where
- Uganda
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- RAND
Hiv
PK of TAF and TDF for PrEP in Pregnant and Postpartum Women
This study will establish benchmarks of TFV-DP concentrations as measures of adherence following daily dosing with Tenofovir Alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF) during pregnancy and postpartum.
- Trial name
- PrEP-PP PK (NCT04937881)
- Testing
- Tenofovir alafenamide, Tenofovir Disoproxil Fumarate
- Where
- South Africa
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Prevention
VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
Background: Human immunodeficiency virus (HIV) is a global health threat. The body uses antibodies to fight infection. VRC07-523LS is an antibody directed against HIV.
- Trial name
- NCT03015181
- Testing
- VRC-HIVMAB075-00-AB
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Study of MVA85A in Healthy Infants
This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection.
- Trial name
- NCT00953927
- Testing
- MVA85A/AERAS-485, Candida Skin Test Antigen
- Where
- 3 sites in South Africa
- Volunteers
- 2,797 people, healthy volunteers welcome
- Sponsor
- Aeras
HIV, Risk Reduction Behavior
A Digital Intervention for HIV Prevention in Black Adolescent Girls
The purpose of this study is to develop and evaluate an innovative behavioral HIV prevention videogame intervention to bolster motivation and provide skill-building opportunities to improve Black adolescent girls' ability to…
- Trial name
- NCT04108988
- Testing
- InvestiDate, Non-Health Related Video Game
- Where
- United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV/AIDS
Using Open Contest and Neuro-influence Experiment to Develop and Evaluate PrEP Promotion Messages for High Risk Men
The aim of this study is to examine the utility of neuroimaging technique to evaluate pre-exposure prophylaxis (PrEP) promotion messages for men who have sex with men (MSM) at risk of HIV in Baltimore.
- Trial name
- NCT04166851
- Testing
- PrEP campaign messages developed via open contest, PrEP campaign messages developed via social marketing approach
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV-infection/AIDS
WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)
The objective of this application is to increase PrEP uptake among women vulnerable to HIV acquisition in the rural South, specifically those seeking care at Federally Qualified Healthcare Centers (FQHC) in rural Alabama.
- Trial name
- PrEP (NCT04373551)
- Testing
- Cultural adaptation of a patient-provider communication tool
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of Alabama at Birmingham
HIV Prevention
Rectal Microbicide Acceptability, Tolerability and Adherence
MTN-035 is a multi-site, randomized-sequence, three-period, open label crossover study that will enroll approximately 210 participants randomized (1:1:1:1:1:1) to one of six sequences of rectal microbicide placebo product…
- Trial name
- NCT03671239
- Where
- 7 sites in United States, Malawi and 3 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Microbicide Trials Network
HIV Infections
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
This study will establish the minimum safety, tolerability and acceptability data needed to support the use of cabotegravir long-acting injection (CAB LA) in an adolescent population, potentially transforming the field of HIV…
- Trial name
- NCT04692077
- Testing
- Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
- Where
- 4 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
- Trial name
- NCT01602822
- Testing
- Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Kenneth H. Mayer, MD
HIV
Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior
The purpose of this study is to examine whether Guy2Guy (G2G), a text messaging-based healthy sexuality and human immunodeficiency virus (HIV) prevention program intervention for 14-18 year gay, bisexual and queer men, is…
- Trial name
- G2G (NCT02113956)
- Testing
- Guy2Guy (G2G)
- Where
- 2 sites in United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Center for Innovative Public Health Research
Misinformation, HIV Vaccine
Protecting Against HIV Vaccine Misinformation With Adolescent Girls and Young Women in South Africa
Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes.
- Trial name
- PROTECT (NCT06700447)
- Testing
- Enhanced inoculation message, Nutrition information
- Where
- South Africa
- Volunteers
- 2,163 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs.
- Trial name
- VRC 611 (NCT04408963)
- Testing
- VRC-HIVMAB0102-00-AB
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
Coaching for HCV and HIV
The objective of this study is to determine the feasibility and acceptability of a peer recovery coach (PRC) intervention to improve linkage to hepatitis C (HCV) and/or human immunodeficiency virus (HIV) care, treatment…
- Conditions
- Hepatitis C, HIV Infections, Opioid-use Disorder
- Trial name
- NCT04314414
- Testing
- PRC brief motivational interview intervention, Phone contact
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Boston Medical Center
HIV Infections, Herpes Genitalis
Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda
This study will determine whether acyclovir, a medicine used to treat herpes simplex virus 2 (HSV-2), can slow down the progression (worsening) of HIV disease in people with both HIV and HSV-2 infections.
- Trial name
- NCT00405821
- Testing
- Acyclovir
- Where
- Uganda
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Get Connected Efficacy Trial
Get Connected (GC) is an online brief intervention that employs individual and systems-level tailoring technology to reduce barriers to HIV prevention care (e.g., HIV/STI testing, PrEP) for YMSM.
- Trial name
- NCT03132415
- Testing
- Get Connected, HIV Test Locator
- Where
- 3 sites in United States
- Volunteers
- 285 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hiv
Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide
Pre-exposure prophylaxis (PrEP) with Truvada™ (tenofovir/emtricitabine), in which an HIV-uninfected individual at high risk for contracting HIV takes antiretroviral medications (one pill daily) to maintain blood and genital drug…
- Trial name
- NCT03350672
- Testing
- FTC/TAF
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Philadelphia Fight
HIV Infections, Staphylococcal Infections
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
This study will prospectively evaluate the prevalence and incidence (over a two year period) of MRSA colonization and infection among HIV-infected military beneficiaries to determine predictors for the development of MRSA…
- Trial name
- MRSA (NCT00631566)
- Testing
- Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%
- Where
- 4 sites in United States
- Volunteers
- 550 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Malaria
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
This will be a double-blinded randomized controlled phase III trial of 782 HIV uninfected pregnant women and the children born to them.
- Trial name
- PROMOTE-BC3 (NCT02793622)
- Testing
- Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy, Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy
- Where
- Uganda
- Volunteers
- 782 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco